MA66538B1 - Bont/a modifiée destinée à être utilisée dans le traitement de la dystonie cervicale - Google Patents

Bont/a modifiée destinée à être utilisée dans le traitement de la dystonie cervicale

Info

Publication number
MA66538B1
MA66538B1 MA66538A MA66538A MA66538B1 MA 66538 B1 MA66538 B1 MA 66538B1 MA 66538 A MA66538 A MA 66538A MA 66538 A MA66538 A MA 66538A MA 66538 B1 MA66538 B1 MA 66538B1
Authority
MA
Morocco
Prior art keywords
bont
modified bont
modified
treatment
administered
Prior art date
Application number
MA66538A
Other languages
English (en)
Inventor
Nicolae GRIGORE
Laurent PONS
Original Assignee
Ipsen Biopharm Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2206357.2A external-priority patent/GB202206357D0/en
Application filed by Ipsen Biopharm Limited filed Critical Ipsen Biopharm Limited
Publication of MA66538B1 publication Critical patent/MA66538B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne le traitement de la dystonie cervicale à l'aide d'une BoNT/a modifiée, comprenant une neurotoxine botulique modifiée A (BoNT/A) destinée à être utilisée dans le traitement de la dystonie cervicale, la BoNT/A modifiée étant administrée par injection intramusculaire à un muscle du cou affecté d'un sujet, la BoNT/A modifiée étant administrée au moyen d'une dose unitaire de 750 pg à 17 000 pg de BoNT/A modifiée, au moins une dose unitaire unique étant administrée au muscle du cou affecté, la dose totale administrée pendant le traitement allant jusqu'à 170 000 pg de BoNT/A modifiée, et la BoNT/A modifiée comprenant une chaîne légère BoNT/A et un domaine de translocation, et un domaine de liaison au récepteur BoNT/B (domaine H<sub>C</sub>). L'invention concerne également des méthodes, des utilisations, des formes posologiques unitaires et des kits associés.
MA66538A 2021-09-16 2022-09-16 Bont/a modifiée destinée à être utilisée dans le traitement de la dystonie cervicale MA66538B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB202113262 2021-09-16
GBGB2206357.2A GB202206357D0 (en) 2022-04-29 2022-04-29 Treatment of cervical dystonia
EP22777691.1A EP4401759B1 (fr) 2021-09-16 2022-09-16 Bont/a modifiée destinée à être utilisée dans le traitement de la dystonie cervicale
PCT/GB2022/052361 WO2023041934A1 (fr) 2021-09-16 2022-09-16 Bont/a modifiée destinée à être utilisée dans le traitement de la dystonie cervicale

Publications (1)

Publication Number Publication Date
MA66538B1 true MA66538B1 (fr) 2026-03-31

Family

ID=83457513

Family Applications (1)

Application Number Title Priority Date Filing Date
MA66538A MA66538B1 (fr) 2021-09-16 2022-09-16 Bont/a modifiée destinée à être utilisée dans le traitement de la dystonie cervicale

Country Status (14)

Country Link
US (1) US20250129354A1 (fr)
EP (2) EP4401759B1 (fr)
JP (1) JP2024534384A (fr)
KR (1) KR20240067070A (fr)
CN (1) CN121534167A (fr)
AU (1) AU2022348206A1 (fr)
CA (1) CA3231083A1 (fr)
DK (1) DK4401759T3 (fr)
ES (1) ES3066341T3 (fr)
FI (1) FI4401759T3 (fr)
MA (1) MA66538B1 (fr)
PL (1) PL4401759T3 (fr)
PT (1) PT4401759T (fr)
WO (1) WO2023041934A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202206353D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
AU2023471835A1 (en) * 2023-11-01 2026-04-30 Ipsen Biopharm Limited Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
DK2154151T3 (da) 2005-09-19 2011-09-05 Allergan Inc Clostridiumtoksinaktiverbare clostridiumtoksiner
AU2009339292B2 (en) * 2008-12-10 2016-01-21 Allergan, Inc. Clostridial toxin pharmaceutical compositions
WO2010120766A1 (fr) 2009-04-14 2010-10-21 Mcw Research Foundation, Inc. Neurotoxine botulinique remaniée
US8853360B2 (en) 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
EP2524963B1 (fr) 2011-05-19 2018-10-31 Ipsen Bioinnovation Limited Procédés de fabrication de polypeptides traités de manière protéolytique
MX359480B (es) 2012-05-30 2018-09-28 President And Fellows Of Harvard College Star Neurotoxina botulínica diseñada.
JP6156954B2 (ja) 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド タンパク分解性にプロセシングされたポリペプチドの製造方法
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
RU2746736C2 (ru) 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins

Also Published As

Publication number Publication date
EP4401759A1 (fr) 2024-07-24
EP4751772A3 (fr) 2026-08-05
EP4751772A2 (fr) 2026-06-03
CA3231083A1 (fr) 2023-03-23
CN121534167A (zh) 2026-02-17
WO2023041934A1 (fr) 2023-03-23
ES3066341T3 (en) 2026-05-12
EP4401759B1 (fr) 2026-02-18
JP2024534384A (ja) 2024-09-20
PL4401759T3 (pl) 2026-06-08
PT4401759T (pt) 2026-04-20
US20250129354A1 (en) 2025-04-24
KR20240067070A (ko) 2024-05-16
FI4401759T3 (fi) 2026-04-21
DK4401759T3 (da) 2026-04-27
AU2022348206A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
Urits et al. Treatment and management of myofascial pain syndrome
Mancini et al. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot
Simon et al. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder
Fietzek et al. Early botulinum toxin treatment for spastic pes equinovarus–a randomized double‐blind placebo‐controlled study
Mittal et al. Botulinum toxin treatment of neuropathic pain
Kaji et al. Effect of ultrahigh‐dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: A double‐blind controlled study
Levesque et al. Botulinum toxin infiltrations versus local anaesthetic infiltrations in pelvic floor myofascial pain: Multicentre, randomized, double-blind study
Pettinati et al. Effect of extended‐release naltrexone (XR‐NTX) on quality of life in alcohol‐dependent patients
Kharkar et al. Intramuscular botulinum toxin in complex regional pain syndrome: case series and literature review
Coelho et al. Treating neuropathic pain and comorbid affective disorders: Preclinical and clinical evidence
MX2023003993A (es) Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina.
Ramachandran et al. Botulinum toxin and its orthopaedic applications
Sevim et al. Comparison of transcutaneous tibial nerve stimulation versus percutaneous tibial nerve stimulation in category IIIB chronic prostatitis/chronic pelvic pain syndrome: A randomized prospective trial
MX2025007211A (es) Anticuerpo anti-cm bxet, conjugado anticuerpo-farmaco y metodo de preparacion de estos y uso de estos
Truong et al. Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes: comparing different botulinum toxin preparations
Arnt Inhibitory effects on the discriminative stimulus properties ofd-amphetamine by classical and newer antipsychotics do not correlate with antipsychotic activity. Relation to effects on the reward system?
Bai et al. Effectiveness of microneedle fractional radiofrequency combined with transcutaneous delivery of botulinum toxin in the management of post‐acne scars
Arnold et al. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder
Benecke Xeomin® in the treatment of cervical dystonia
AU2011315962A1 (en) Targeted delivery of Targeted Exocytosis Modulators to the sphenopalatine ganglion for treatment of headache disorders
BR112022010042A2 (pt) Composições de hialuronidase e métodos de uso da mesma para tratar celulite
Akimoto et al. SCH23390, a dopamine D1 receptor antagonist, suppressed scratching behavior induced by compound 48/80 in mice
Unlu et al. Botulinum toxin injection of the subscapularis muscle
Park et al. Faster recovery in patients with facial nerve palsy treated with contralateral botulinum toxin injection: a case-control study
Belen Management of Spasticity Caused by Thrombotic Brain Injury with Incobotulinumtoxina in a Young Patient: A New Paradigm